Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04711759
Other study ID # 180814001
Secondary ID 1191709
Status Completed
Phase N/A
First received
Last updated
Start date January 27, 2021
Est. completion date December 17, 2022

Study information

Verified date January 2021
Source Pontificia Universidad Catolica de Chile
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

High-flow nasal cannula (HFNC) is a rather novel system to provide oxygen therapy, which provides flows up to 60 liters/minute (LPM) of heated and humidified gas through nasal prongs. HFNC is increasingly being used in patients with acute respiratory failure. In healthy volunteers and in patients with acute respiratory failure it has been shown to induce several effects beyond those expected for a standard oxygen therapy, such as increased carbon dioxide (CO2) clearance and positive airway pressure. One of the potential indications for HFNC is to facilitate weaning from mechanical ventilation and extubation. As weaning failure is one of the most complex challenges in mechanically ventilated patients, the use of HFNC after extubation, in order to prevent reintubation, has been evaluated in some clinical trials, with promising results. However, the role of HFNC postextubation is still controversial, and information regarding its effects on the pathophysiologic mechanisms of weaning failure is lacking. The goal of this proposal is to compare the acute physiologic effects of postextubation HFNC versus standard oxygen therapy, in critically ill patients, on relevant mechanisms related to weaning failure: work of breathing, lung function, systemic hemodynamics. This will be a randomized crossover study which will include critically ill mechanically ventilated patients, who fulfill criteria indicating they may be ready for weaning from mechanical ventilation, and in whom a spontaneous breathing trial (SBT) is planned to determine if they should be extubated. After checking eligibility and obtaining informed consent, patients will be monitored with an esophageal catheter (esophageal / gastric pressures to determine work of breathing, and electric activity of diaphragm to determine neuromechanical coupling), and a noninvasive ventilation monitor (electric impedance tomography to assess global and regional ventilation). Work of breathing, lung function, and systemic hemodynamics will be assessed during the SBT. Inclusion in the study will be confirmed only if they pass the SBT and are extubated. During the first 2 hours after extubation patients will undergo one hour of HFNC and one hour of standard oxygen therapy, with the crossover sequence being randomized previously at the time of inclusion, and with assessments repeated at the end of each treatment period.


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date December 17, 2022
Est. primary completion date November 17, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Mechanical ventilation (MV) through an orotracheal tube for at least 48 hours - PaO2 /FiO2 ratio = 300 mmHg - Potential for weaning as determined in routine daily screening (precipitating cause leading to MV in resolution, adequate oxygenation (PaO2/FiO2 =150 mmHg with FiO2 =0.4 and PEEP =8 cm H2O), arterial pH >7.25, hemodynamic stability (no vasopressors or Noradrenaline =0.1 mcg/kg/min), temperature <38°C, presence of inspiratory effort and appropriate spontaneous cough, and the patient is not receiving sedatives and is awake and able to follow simple commands) - Decision to perform a spontaneous breathing trial by the attending physician Exclusion Criteria: - Patients ventilated for decompensated chronic obstructive pulmonary disease - Contraindications to HFNC, which include abnormalities or surgery of the face, nose, or airway that preclude an appropriate-fitting nasal cannula. - Contraindications for esophageal balloon catheter insertion (eg. severe coagulopathy, esophageal varices, and history of esophageal or gastric surgery) - Contraindication for use of electric impedance tomography (eg. Pacemaker) - Presence of tracheostomy - Refusal to participate by the attending physician - Do not resuscitate order

Study Design


Related Conditions & MeSH terms


Intervention

Device:
High flow nasal cannula
High flow nasal cannula will be provided through a commercial device (AIRVO2 + Optiflow nasal cannula, Fisher & Paykel), at 50 LPM and at the same FiO2 applied during the spontaneous breathing trial.
Standard oxygen therapy
Standard oxygen therapy will be provided through a Venturi mask and O2 flow will be adjusted to keep the same FiO2 applied during the spontaneous breathing trial.

Locations

Country Name City State
Chile Hospital Clínico UC Christus Santiago Region Metropolitana

Sponsors (2)

Lead Sponsor Collaborator
Pontificia Universidad Catolica de Chile Fondo Nacional de Desarrollo Científico y Tecnológico, Chile

Country where clinical trial is conducted

Chile, 

References & Publications (3)

Fernandez R, Subira C, Frutos-Vivar F, Rialp G, Laborda C, Masclans JR, Lesmes A, Panadero L, Hernandez G. High-flow nasal cannula to prevent postextubation respiratory failure in high-risk non-hypercapnic patients: a randomized multicenter trial. Ann Int — View Citation

Hernandez G, Vaquero C, Gonzalez P, Subira C, Frutos-Vivar F, Rialp G, Laborda C, Colinas L, Cuena R, Fernandez R. Effect of Postextubation High-Flow Nasal Cannula vs Conventional Oxygen Therapy on Reintubation in Low-Risk Patients: A Randomized Clinical — View Citation

Mauri T, Turrini C, Eronia N, Grasselli G, Volta CA, Bellani G, Pesenti A. Physiologic Effects of High-Flow Nasal Cannula in Acute Hypoxemic Respiratory Failure. Am J Respir Crit Care Med. 2017 May 1;195(9):1207-1215. doi: 10.1164/rccm.201605-0916OC. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Pressure time-product (PTP) per minute (cmH2O x s/min) PTPmin will be assessed through an esophageal Neurovent catheter. 60 minutes after starting high flow nasal cannula or standard oxygen therapy
Primary Delta end-expiratory lung index (EELI) Delta EELI will be obtained from electric impedance tomography (EIT) and measured relative to the tidal volume. 60 minutes after starting high flow nasal cannula or standard oxygen therapy
Primary Brain natriuretic peptide (BNP) plasma levels 60 minutes after starting high flow nasal cannula or standard oxygen therapy
Secondary Pressure time-product per breath (cmH2O x s) PTP will be assessed through an esophageal Neurovent catheter. 60 minutes after starting high flow nasal cannula or standard oxygen therapy
Secondary Peak electric activity of the diaphragm (EAdi) EAdi will be measured in uV through a Neurovent catheter connected to a Servo-i ventilator 60 minutes after starting high flow nasal cannula or standard oxygen therapy
Secondary Neuroventilatory efficiency Vt / EAdi (ml / uV) 60 minutes after starting high flow nasal cannula or standard oxygen therapy
Secondary Neuromechanical efficiency Ratio of the (Paw-PEEP) divided by EAdi during inspiratory occlusion (cmH2O / uV) 60 minutes after starting high flow nasal cannula or standard oxygen therapy
Secondary Global inhomogeneity index index derived from EIT and calculated from the sum of the impedance changes of each pixel with respect to its median (in absolute values), divided by the sum of the impedance values of each pixel 60 minutes after starting high flow nasal cannula or standard oxygen therapy
Secondary PaO2 / FiO2 Parameter of oxygen exchange calculated as the ratio of PaO2 / FiO2 60 minutes after starting high flow nasal cannula or standard oxygen therapy
See also
  Status Clinical Trial Phase
Completed NCT02894177 - Transcutaneous Carbon Dioxide Pressure (tcPCO2) Monitoring for the Prediction of Extubation Failure in the ICU N/A
Recruiting NCT05114551 - ICU Predictive Score of WEaning Success in Patients At Risk of Extubation Failure
Completed NCT04011852 - The Role of Chest Electrical Impedance Tomography in the Pediatric Ventilator Weaning
Recruiting NCT02921334 - Early Tracheotomy for Switching Between Invasive and Noninvasive Ventilation to Facilitate Weaning N/A
Recruiting NCT02921347 - Switching Between Invasive and Noninvasive Ventilation to Facilitate Weaning in Difficult-weaning Patients N/A
Recruiting NCT06055413 - Home-based Optimization of Mechanical Ventilation in Children N/A
Active, not recruiting NCT04023643 - Pediatric Ventilation Weaning N/A
Completed NCT05254691 - WOB and Paediatric Mechanical Ventilation N/A
Recruiting NCT05999526 - Mechanical Ventilation Reconnection for One Hour After Spontaneous Breathing Trial N/A
Active, not recruiting NCT02820090 - The Predictive Effect of the Inflammatory Response on the Evacuation of Mechanical Ventilation and the Mechanism N/A
Recruiting NCT01131377 - Acetazolamide Facilitates Ventilator Weaning N/A
Completed NCT02412202 - Echocardiographic Detection of Extravascular Lung Water Increase During Weaning From Mechanical Ventilation N/A
Completed NCT00445289 - Automatic Control of Pressure Support Ventilation in Surgical Intensive Care Units N/A
Recruiting NCT05380687 - Time Course of Neuro-ventilatory Efficiency During a Spontaneous Breathing Training N/A
Terminated NCT01535755 - A Protocol to Wean From Noninvasive Mechanical Ventilation N/A
Completed NCT03433105 - Oxygen Uptake in Weaning of Patients From Prolonged Mechanical Ventilation
Completed NCT00505804 - A Comparison of Dexmedetomidine and Haloperidol in Patients With Intensive Care Unit (ICU)-Associated Agitation and Delirium Phase 2
Completed NCT02946502 - Handgrip Strength Value in Predicting Mechanical Ventilation Weaning N/A
Completed NCT03673683 - Sedation and Weaning in Children Requiring Invasive Mechanical Ventilation N/A
Terminated NCT03019107 - Breath Synchronized Abdominal Muscle Stimulation to Facilitate Ventilator Weaning: a Pilot Study